Chiesi Global Rare Diseases has secured European Commission approval to expand the indication of lomitapide (LOJUXTA® capsules) to include pediatric patients aged five years and older diagnosed with homozygous familial hypercholesterolaemia (HoFH), an ultra-rare genetic disorder characterized by severely elevated LDL-cholesterol levels. The regulatory green light broadens a previously adult-only EU label and marks a significant step for a condition that affects an estimated one in 300,000 individuals globally.
Lomitapide functions as a microsomal triglyceride transfer protein (MTP) inhibitor, directly blocking the assembly and secretion of apolipoprotein B-containing lipoproteins in both the liver and intestine. Unlike statin-based therapies that upregulate LDL-receptor activity, lomitapide reduces LDL-cholesterol at the production level — a mechanism particularly relevant in HoFH patients whose receptor function is severely compromised or absent. The compound does not carry a structure-function claim in the nutraceutical sense; it is a prescription pharmaceutical, but its lipid-modulating pathway continues to inform upstream research into novel finished formulations targeting LDL biomarkers in the broader cardiovascular wellness segment.
The cardiovascular health supplement and functional food category remains one of the largest in the global nutraceutical market, with plant sterols, omega-3 fatty acids, red yeast rice extracts, and soluble fibers such as beta-glucan occupying the accessible, self-care end of the lipid-management spectrum. While lomitapide sits firmly in the pharmaceutical lane, regulatory expansions like this one signal growing institutional attention to LDL as a clinical endpoint across age groups — a trend that nutraceutical developers and co-manufacturing partners are increasingly referencing when positioning heart-health portfolios to retail and clinical channels alike. Industry observers tracking the cardiovascular and heart-health supplement space note that orphan-drug approvals often raise consumer awareness of underlying conditions, indirectly lifting demand for preventive, diet-based interventions.
For operators formulating in the lipid-management space, the pediatric HoFH approval is a signal worth monitoring. As rare-disease diagnoses improve through genetic screening, a cohort of young patients and their caregivers will be navigating long-term lipid management — creating adjacency opportunities for dietitian-recommended functional foods, GRAS-affirmed plant sterol esters, and omega-3 finishing products positioned as adjunct dietary support. Chiesi's EU label expansion, covered across the Food & Beverage Magazine network, also underscores how pediatric dosing data — notoriously difficult to generate — can unlock entirely new patient populations once compiled. Nutraceutical brands pursuing pediatric and family health positioning should note the regulatory bar that pharmaceutical counterparts are clearing, as functional food claims in this demographic face analogous scrutiny from EFSA and FDA alike.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.